Cisplatin administration to gynecologic cancer patients: Long term effects on hearing

Cancer

Volumn 78, Issue 8, 1996, Pages 1798-1804

  Laurell, Göran ^a   Beskow, Catharina ^a   Frankendal, Bo ^a   Borg, Erik ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

Author keywords

age; female; hearing handicap; ototoxic side effect

Indexed keywords

CISPLATIN;

ADULT; AGED; ARTICLE; AUDIOGRAPHY; AUDIOMETRY; AUDITORY THRESHOLD; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; GYNECOLOGIC CANCER; HEARING LOSS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; OTOTOXICITY; OVARY CARCINOMA; PRIORITY JOURNAL; SOCIAL DISABILITY;

ADULT; AGED; AUDIOMETRY; CISPLATIN; FEMALE; FOLLOW-UP STUDIES; GENITAL NEOPLASMS, FEMALE; HEARING LOSS, BILATERAL; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 0029745120     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961015)78:8<1798::AID-CNCR22>3.0.CO;2-S     Document Type: Article

References (20)

1. Neijt JP. Treatment of advanced ovarian cancer: 10 years of experience. Ann Oncol 1992;3:17-27.
2. Boivin J-F. Second cancers and other late side effects of cancer treatment. Cancer 1990;65:770-5.
3. Ostrow S, Egorin MJ, Hahn D, Markus S, LeRoy A, Chang P, et al. Cis-dichlorodiammine platinum and adriamycin therapy for advanced gynecological and genitourinary neoplasms. Cancer 1980;46:1715-21.
4. Brown RL, Nuss RC, Patterson R, Irey J. Audiometric monitoring of cis-platinum ototoxicity. Gynecol Oncol 1983;16:254-62.
5. Melamed LB, Selim MA, Schuchman D. Cisplatin ototoxicity in gynecologic cancer patients. Cancer 1985;55:41-3.
6. Laurell G, Borg E. Ototoxicity of cisplatin in gynaecological cancer patients. Scand Audiol 1988;17:241-7.
7. Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, Tattersail HN. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep 1982;66:19-23.
8. Vermorken JB, Kapteijn TS, Hart AAM, Pinedo HM. Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 1983;19(1):53-8.
9. Laurell G, Engström B. The ototoxic effect of cisplatin on guinea pigs in relation to dosage. Hear Res 1989;38:27-34.
10. Laurell G, Jungnelius U. High-dose cisplatin treatment. Hearing loss and plasma concentrations. Laryngoscope 1990;100:724-34.
11. Koppelman J, Budnick AS, Kramer MB, Sessions RB, Wong GY. Ototoxixity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing. Laryngoscope 1988;88:858-64.
12. Tothill P, Klys HS, Matheson LM, McKay K, Smyth JF. The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy. Eur J Cancer 1992;28:1358-61.
13. Jervall L, Dryselius H, Arlinger S. Comparison of manual and computer-controlled audiometry using identical procedures. Scand Audiol 1983;12:209-13.
14. Spoor A. Prebyacusis values in relation to noise induced hearing loss, Int Audiol 1967;6:48-57.
15. Wiltshaw E, Kroner T. Phase II study of cis-dichlorodiammineplatinum (II) (NSC-1198875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep 1976;60:55-60.
16. Aguilar-Markulis NV, Beckley S, Priore R, Mettlin C. Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients. J Surg Oncol 1981;16:111-23.
17. Brummett RE, Morrison RB. The incidence of aminoglycoside antibiotic-induced hearing loss. Arch Otolaryngol Head Neck Surg 1990;116:406-10.
18. Boyer M, Raghavan D, Harris PJ, Lietsch J, Bleasel A, Walsh J, et al. Lack of late toxicity in patients treated with cisplatinbased combination chemotherapy for metastatic testicular cancer. J Clin Oncol 1990;8(1):21-6.
19. Stuart NSA, Woodroffe CM, Grundy R, Cullen MH. Longterm toxicity of chemotherapy for testicular cancer - the cost of cure. Br J Cancer 1990;61:479-84.
20. Osanto S, Bukman A, Van Hoek F, Sterk PJ, De Laat JAPM, Hermans J. Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 1992;10(4):574-9.